Investigation of the enhanced antitumour potency of CD46-specific chimeric antigen receptor-T cells in human colorectal cancer liver metastases after combination with nanotherapeutics
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: CAR-T cell therapy research · Immunotherapy and Immune Responses · Immune Cell Function and Interaction
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Global colorectal cancer burden in 2020 and projections to 204010.1016/j.tranon.2021.101174 ↗
2. Cancer-derived exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts10.1038/s41419-022-04506-4 ↗
3. KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration10.1002/hep.32383 ↗
4. Diagnosis and treatment of metastatic colorectal cancer: a review10.1001/jama.2021.0106 ↗
5. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer10.1056/NEJMoa0805019 ↗
6. Colorectal liver metastasis: molecular mechanism and interventional therapy10.1038/s41392-022-00922-2 ↗
7. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer10.1002/ajh.25418 ↗
8. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities10.1038/nrclinonc.2017.148 ↗
9. CAR T-cell therapy of solid tumors10.1038/icb.2016.128 ↗
10. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo10.1038/nbt.4195 ↗
11. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial10.1016/S0140-6736(14)61403-3 ↗
12. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia10.1182/blood-2012-06-438002 ↗
13. The CD46-Jagged1 interaction is critical for human TH1 immunity10.1038/ni.2454 ↗
14. Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation10.1038/ni810 ↗
15. CD46-induced immunomodulatory CD4+ T cells express the adhesion molecule and chemokine receptor pattern of intestinal T cells10.4049/jimmunol.181.4.2544 ↗
16. CD46 in innate and adaptive immunity: an update10.1111/j.1365-2249.2011.04400.x ↗
17. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus10.1158/0008-5472.CAN-04-0884 ↗
18. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors10.1016/S0161-5890(03)00112-3 ↗
19. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer10.1172/jci.insight.121497 ↗
20. Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?10.7150/thno.59953 ↗
21. Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy10.1016/j.ccell.2022.01.006 ↗
22. Nanomaterials for T-cell cancer immunotherapy10.1038/s41565-020-00822-y ↗
23. Amplified cancer immunotherapy of a surface-engineered antigenic microparticle vaccine by synergistically modulating tumor microenvironment10.1021/acsnano.9b03288 ↗
24. Encapsulation of platinum prodrugs into PC7A polymeric nanoparticles combined with immune checkpoint inhibitors for therapeutically enhanced multimodal chemotherapy and immunotherapy by activation of the STING pathway
25. Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR-17-5p10.1158/0008-5472.CAN-18-3880 ↗
26. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma10.1002/hep.21437 ↗
27. Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation10.1182/blood-2005-07-2951 ↗
28. Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections10.1016/j.coi.2021.04.005 ↗
29. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors10.1158/0008-5472.CAN-14-0697 ↗
30. Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors10.4161/21505594.2014.988098 ↗
31. Colonic mucus-accumulating tungsten oxide nanoparticles improve the colitis therapy by targeting Enterobacteriaceae10.1016/j.nantod.2021.101234 ↗
32. Matairesinol nanoparticles restore chemosensitivity and suppress colorectal cancer progression in preclinical models: role of lipid metabolism reprogramming10.1021/acs.nanolett.3c00035 ↗
33. SiRNA-based delivery nanoplatform attenuates the CRC progression via HIF1α-AS210.1016/j.nantod.2022.101667 ↗
34. Therapeutic m6A Eraser ALKBH5 mRNA-loaded exosome–liposome hybrid nanoparticles inhibit progression of colorectal cancer in preclinical tumor models10.1021/acsnano.3c03050 ↗
35. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue10.1136/gut.2008.158824 ↗
36. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer10.1158/0008-5472.CAN-05-0141 ↗
37. Characteristics of immunosuppressive regulatory T cells in cutaneous squamous cell carcinomas and role in metastasis10.1016/S0140-6736(15)60374-9 ↗
38. The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases10.1016/j.immuni.2018.12.001 ↗
39. T regulatory cells and priming the suppressive tumor microenvironment10.3389/fimmu.2019.02453 ↗
40. Deciphering and reversing tumor immune suppression10.1016/j.immuni.2013.07.005 ↗
41. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin
42. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo10.1073/pnas.0408197102 ↗
43. Tregs and rethinking cancer immunotherapy10.1172/JCI31202 ↗
44. Dysfunctional T regulatory cells in multiple myeloma10.1182/blood-2005-08-3101 ↗
45. Effect of PDI overexpression on recombinant protein secretion in CHO cells10.1021/bp000107q ↗
46. Live Cell Membranome cDNA screen: a novel homogenous live cell binding assay to study membrane protein-ligand interaction10.1177/2472555219873069 ↗
47. The dark side of IFN-gamma: its role in promoting cancer immunoevasion10.3390/ijms19010089 ↗
48. Interferon gamma limits the effectiveness of melanoma peptide vaccines10.1182/blood-2010-08-298117 ↗
49. Proteomic profiling of the human T-cell nucleolus10.1016/j.molimm.2011.09.005 ↗
50. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion10.1126/science.1203486 ↗
51. Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers10.18632/oncotarget.9427 ↗
52. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape10.1038/nm.2830 ↗
53. Suppression of tumour-specific CD4(+) T cells by regulatory T cells is associated with progression of human colorectal cancer10.1136/gutjnl-2011-300970 ↗
54. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma
55. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial10.1038/s41591-020-1081-3 ↗
56. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia10.1038/s41375-019-0488-7 ↗
57. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia10.1056/NEJMoa1215134 ↗
58. Characterization of basigin isoforms and the inhibitory function of basigin-3 in human hepatocellular carcinoma proliferation and invasion10.1128/MCB.05160-11 ↗
59. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma10.1038/s41467-020-18444-2 ↗
60. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity10.1158/0008-5472.CAN-15-0139 ↗